The differentiation of mesenchymal stromal cells (MSCs) is influenced by numerous epigenetic factors, among which microRNAs (miRNAs) play a key role. MiRNAs act as regulators of gene expression important for osteogenesis and help maintain skeletal tissue homeostasis. Numerous studies have demonstrated that dysregulation of specific miRNAs is not only associated with osteogenesis but also with the development of bone diseases such as osteoporosis. Osteoporosis represents one of the major public health challenges, affecting approximately 200 million people worldwide. In this master’s thesis, we studied the impact of selected miRNAs (hsa-miR-375-3p, hsa-miR-363-3p, hsa-miR-20b-5p, hsa-miR-133a-3p, and hsa-miR-31-3p) on the osteogenic differentiation of MSCs. The MSCs used as the cellular model for the study were prepared through lentiviral transduction, resulting in either overexpression or knockdown of the selected miRNAs. In these cells we analyzed the expression of key osteogenic markers (ALPL, BGLAP, COL1A1 and RUNX2), using quantitative real-time polymerase chain reaction. The results were quantified by relative quantification using the standard curve method and statistically evaluated using Student's t-test. These results were further compared with Von Kossa staining. Based on the results, we assessed the influence of miRNAs on the osteogenesis of MSCs. The results of the thesis confirm the hypothesis that altered miRNA expression significantly affects osteogenic differentiation of MSCs. Among the studied miRNAs, hsa-miR-363-3p showed the greatest potential as a biological marker and/or therapeutic target, as qPCR results showed statistically significant differences in the expression of osteogenic genes compared to control samples, and qPCR results were consistent with Von Kossa staining. Our results contribute to a better understanding of the role of miRNAs in osteogenesis and their potential in the diagnosis and treatment of osteoporosis. Despite the promising findings, the use of miRNAs in clinical practice remains a challenge due to their nonspecificity, instability, and lack of efficient delivery systems. Further research using clinical samples and in vivo models are necessary for better understanding and to enable the clinical implementation of miRNAs.
|